Type_NN
II_CD
estrogen_NN
binding_NN
sites_NNS
in_IN
human_JJ
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
:_:
variations_NNS
during_IN
the_DT
menstrual_JJ
cycle_NN
._.

We_PRP
have_VBP
previously_RB
reported_VBN
that_IN
human_JJ
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
-LRB-_-LRB-
PBMC_NN
-RRB-_-RRB-
contain_VBP
type_NN
II_CD
estrogen_NN
binding_NN
sites_NNS
-LRB-_-LRB-
type_NN
II_CD
EBS_NNS
-RRB-_-RRB-
._.

In_IN
this_DT
study_NN
,_,
the_DT
fluctuations_NNS
of_IN
type_NN
II_CD
EBS_NNS
during_IN
the_DT
menstrual_JJ
cycle_NN
were_VBD
analyzed_VBN
in_IN
6_CD
normally_RB
menstruating_VBG
women_NNS
._.

Approximately_RB
3_CD
times_NNS
higher_JJR
levels_NNS
of_IN
type_NN
II_CD
EBS_NNS
were_VBD
found_VBN
in_IN
the_DT
periovulatory_JJ
period_NN
with_IN
respect_NN
to_TO
both_CC
follicular_JJ
and_CC
luteal_JJ
phases_NNS
._.

In_IN
postmenopausal_JJ
women_NNS
the_DT
mean_NN
type_NN
II_CD
EBS_NN
levels_NNS
were_VBD
similar_JJ
to_TO
those_DT
observed_VBN
in_IN
the_DT
follicular_JJ
phase_NN
of_IN
the_DT
cycle_NN
._.

However_RB
,_,
in_IN
3_CD
postmenopausal_JJ
patients_NNS
a_DT
short_JJ
course_NN
of_IN
estrogen_NN
or_CC
tamoxifen_NN
resulted_VBD
in_IN
a_DT
marked_JJ
increase_NN
of_IN
type_NN
II_CD
EBS_NN
levels_NNS
._.

Tamoxifen_NN
was_VBD
also_RB
found_VBN
to_TO
compete_VB
with_IN
17_CD
beta-estradiol_NN
for_IN
type_NN
II_CD
EBS_NNS
in_IN
PBMC_NN
,_,
although_IN
to_TO
a_DT
lesser_JJR
extent_NN
than_IN
diethylstilbestrol_NN
._.

